Abliva
0.137 SEK +4.27%Be the first to follow this company
Abliva is a pharmaceutical company. The company develops drugs for the treatment of primary mitochondrial diseases. These congenital, rare and often very serious diseases occur when the cell's energy supply, the mitochondria, does not function properly. The portfolio includes projects in various stages and ranges from the early detection phase to the clinical phase. The company was previously known as NeuroVive Pharmaceutical.
Revenue
140K
EBIT %
-68,964.29 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ABLI
Daily low / high price
0.122 / 0.139
SEK
Market cap
184.33M SEK
Turnover
209.07K SEK
Volume
1.5M
Financial calendar
Interim report
2024-08-22
Interim report
2024-11-21
Annual report
2025-02-21
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Hadean Capital I AS | 22.4 % | 22.4 % |
Oslo Pensjonsforsikring AS | 14.9 % | 14.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Amended number of shares and votes in Abliva AB (publ)
Abliva Announces Completion of 24 Weeks of Dosing in Wave 1 of the FALCON Study of KL1333 in Primary Mitochondrial Disease
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools